Dr. Annette Stemhagen, SVP & Chief Scientific Officer, speaks about Pregnancy Exposure Registries (PERs) and why partnering with an experienced team is so vital.
April 24, 20254 min read
UBC Named a Pharmacovigilance Leader in Everest Group PV Operations PEAK Matrix Assessment 2025
UBC has been recognized by Everest Group as a leader in its 2025 Pre-approval Pharmacovigilance (PV) PEAK Matrix®, and a major contender in the Post-approval category. The recognition highlights UBC’s strength in delivering innovative, compliant, and patient-focused PV solutions across the drug development lifecycle.